FLT3
10 drugs Oncology
4
approved indications
10
Approved Drugs
9
Companies
19
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (9 companies)
✓ All 10 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (19 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
DAIICHI SANKYO INC 2 drugs
CPPI CV 1 drug
Novartis 1 drug
By Therapeutic Area
Other 6 drugs
Oncology 4 drugs
By Therapeutic Area
Other 6 drugs
SUTENT, INREBIC, GAVRETO, ICLUSIG +2 more
Oncology 4 drugs
RYDAPT, SUNITINIB MALATE, VANFLYTA, XOSPATA
Indications Treated
Gastrointestinal Stromal TumorRenal Cell CarcinomaPancreatic Neuroendocrine TumorMyelofibrosisMetastatic RET fusion-positive non-small cell lung cancerAdvanced or metastatic RET fusion-positive thyroid cancerAcute Myeloid LeukemiaPolycythemia VeraEssential ThrombocythemiaGastrointestinal stromal tumor (GIST)Advanced renal cell carcinoma (RCC)Adjuvant treatment of renal cell carcinoma (RCC) at high risk of recurrence following nephrectomyProgressive, well-differentiated pancreatic neuroendocrine tumors (pNET)Aggressive Systemic MastocytosisSystemic Mastocytosis with Associated Hematological NeoplasmMast Cell LeukemiaTenosynovial Giant Cell TumorPhiladelphia Chromosome-Positive Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia
All Drugs Targeting FLT3
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| SUTENT | CPPI CV | 2006 | 4 | |
| RYDAPT | Novartis | 2017 | 4 | Oncology |
| SUNITINIB MALATE | NATCO PHARMA | 2021 | 3 | Oncology |
| INREBIC | Bristol-Myers Squibb | 2019 | 3 | |
| GAVRETO | BLUEPRINT MEDICINES | 2020 | 2 | |
| ICLUSIG | Takeda | 2012 | 2 | |
| VONJO | SOBI | 2022 | 1 | |
| VANFLYTA | DAIICHI SANKYO INC | 2023 | 1 | Oncology |
| XOSPATA | ASTELLAS | 2018 | 1 | Oncology |
| TURALIO | DAIICHI SANKYO INC | 2019 | 1 |